Keros Therapeutics, Inc. Insider Trading for May 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Keros Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Keros Therapeutics, Inc. for May 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Option Exercise | M | 0.48 | 1,000 | 480 | 99,211 | |
| May 13 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Option Exercise | M | 0.48 | 1,000 | 480 | 99,211 | |
| May 13 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 50.15 | 1,000 | 50,150 | 0 | 1,000 to 0 (-100.00 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 50.15 | 1,000 | 50,150 | 0 | 1,000 to 0 (-100.00 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Buy | M | 0.48 | 1,000 | 480 | 1,000 | 0 to 1,000 |
| May 13 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Buy | M | 0.48 | 1,000 | 480 | 1,000 | 0 to 1,000 |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.30 | 500 | 150 | 7,793 | |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.30 | 500 | 150 | 7,793 | |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.11 | 6,220 | 684 | 0 | |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.11 | 6,220 | 684 | 0 | |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.30 | 2,650 | 795 | 132,355 | |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.30 | 2,650 | 795 | 132,355 | |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.30 | 500 | 150 | 77,907 | 77.4 K to 77.9 K (+0.65 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.30 | 500 | 150 | 77,907 | 77.4 K to 77.9 K (+0.65 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.11 | 6,220 | 684 | 77,407 | 71.2 K to 77.4 K (+8.74 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.11 | 6,220 | 684 | 77,407 | 71.2 K to 77.4 K (+8.74 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 50.00 | 2,650 | 132,500 | 71,187 | 73.8 K to 71.2 K (-3.59 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 50.00 | 2,650 | 132,500 | 71,187 | 73.8 K to 71.2 K (-3.59 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.30 | 2,650 | 795 | 73,837 | 71.2 K to 73.8 K (+3.72 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.30 | 2,650 | 795 | 73,837 | 71.2 K to 73.8 K (+3.72 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 54.35 | 339 | 18,425 | 383,205 | 383.5 K to 383.2 K (-0.09 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 54.35 | 520 | 28,262 | 572,305 | 572.8 K to 572.3 K (-0.09 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 53.73 | 780 | 41,909 | 383,544 | 384.3 K to 383.5 K (-0.20 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 53.73 | 1,196 | 64,261 | 572,825 | 574 K to 572.8 K (-0.21 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.48 | 616 | 36,640 | 384,324 | 384.9 K to 384.3 K (-0.16 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.48 | 942 | 56,030 | 574,021 | 575 K to 574 K (-0.16 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.78 | 4,506 | 264,863 | 384,940 | 389.4 K to 384.9 K (-1.16 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.78 | 6,905 | 405,876 | 574,963 | 581.9 K to 575 K (-1.19 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 57.86 | 4,600 | 266,156 | 389,446 | 394 K to 389.4 K (-1.17 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 57.86 | 7,054 | 408,144 | 581,868 | 588.9 K to 581.9 K (-1.20 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 56.63 | 4,460 | 252,570 | 394,046 | 398.5 K to 394 K (-1.12 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 56.63 | 6,841 | 387,406 | 588,922 | 595.8 K to 588.9 K (-1.15 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 56.04 | 3,509 | 196,644 | 398,506 | 402 K to 398.5 K (-0.87 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 56.04 | 5,383 | 301,663 | 595,763 | 601.1 K to 595.8 K (-0.90 %) |